Research

Clinical Trials & Research

CMC’s New England Heart & Vascular Institute participates in a number of multicenter clinical trials collaborating with institutions around the world. Participating in clinical trials allows our experts to conduct quality research that is at the forefront of technology and innovation, and provides our patients’ access to leading-edge care. We ensure that research performed at CMC is ethical, compliant and relevant.  

For additional information on our clinical trials or to refer a patient, contact The New England Heart & Vascular Institute at 603.669.0413.

Currently, CMC’s New England Heart & Vascular Institute is participating in the following clinical trials:

Cardiometabolic  

• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Electrophysiology Clinical Trials  

• A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation (ADVANTAGE AF)
• INTERRUPT AF: Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation
• RHAPSODY: RHythmia mAPping and Signal acquisitiOn for Data analYsis 
• SyncAV Post-Market Trial (SyncAV)
• The CONFORM Pivotal Trial
• Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation Ablation (ULTRA-HFIB)
• Pulsed Field Ablation (PFA) Versus Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation (AVANT GUARD)

Heart Failure Clinical Trials

• Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)

Interventional Clinical Trials

• Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease (EMPOWER CAD)
• International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry
• Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function (PROTECT IV)
• The SELUTION DeNovo Study

Non-Invasive Clinical Trials 

• Testing Automated Echocardiography

Structural Heart Clinical Trials 

• Evolut™ EXPAND TAVR II Pivotal Trial
• The HALT Biomarker Study (HALT)
• Amplatzer PFO Occluder Post-marketing Surveillance Study (PFO PMS Jpn)
• ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation (ENVISION)

Studies in follow-up (no longer enrolling in)

Electrophysiology Clinical Trials  

• Accelerometer Sensing for Micra AV Study (AccelAV)
• Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO)
• CHAMPION-AF Clinical Trial (CHAMPION-AF)
• The CONFORMAL Early Feasibility Study
• OPTION: Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation (OPTION)

Structural Heart Clinical Trials 

• PK Papyrus (Humanitarian Use Device)